Lunesta Overdose & Accidental Excess Dose: What Clinicians and Patients Need to Know

How Eszopiclone Works: The Mechanism Behind Its Toxicity

Eszopiclone is the active S(+)-enantiomer of racemic zopiclone. It binds selectively to the benzodiazepine site on GABA-A receptors, increasing chloride ion influx and producing sedation, anxiolysis, and muscle relaxation. Understanding this mechanism explains exactly why overdose is dangerous: dose-dependent receptor saturation deepens CNS depression nonlinearly.

GABA-A Receptor Pharmacology

GABA-A receptors are ligand-gated chloride channels distributed throughout the brain, spinal cord, and brainstem respiratory centers. Eszopiclone acts as a positive allosteric modulator, meaning it does not activate the receptor alone but amplifies the effect of endogenous GABA. At therapeutic doses (1 to 3 mg), this produces sleep onset within 15 to 30 minutes. At supratherapeutic doses, the same mechanism suppresses brainstem respiratory drive and can cause apnea in vulnerable patients.

The receptor subtypes most relevant to toxicity are those containing alpha-1 subunits (mediating sedation and amnesia) and alpha-2/alpha-3 subunits (mediating muscle relaxation and anxiolysis). Eszopiclone binds these with moderate selectivity compared to classic benzodiazepines, but the clinical toxidrome at high doses is nearly identical to benzodiazepine poisoning. A 2005 pharmacokinetic and pharmacodynamic review confirmed that eszopiclone's receptor affinity profile overlaps substantially with triazolam and temazepam at supramaximal concentrations.

Pharmacokinetics Relevant to Overdose

• Peak plasma concentration (Tmax): approximately 1 hour after oral ingestion
• Half-life: 6 hours in healthy adults; extended to 9 hours in patients older than 65
• Protein binding: 52 to 59%, limiting dialysis efficacy
• Metabolism: CYP3A4 and CYP2E1 hepatic metabolism to inactive (S)-N-desmethylzopiclone and active (S)-zopiclone-N-oxide
• Renal excretion: less than 10% unchanged drug in urine

The 6-hour half-life means a patient who takes 30 mg (10 times the maximum therapeutic dose) at midnight could still have significant plasma levels at noon the next day. Concurrent CYP3A4 inhibitors such as ketoconazole, clarithromycin, or ritonavir may double plasma exposure, turning a moderate excess dose into a severe one. The FDA label for eszopiclone notes that coadministration with 400 mg ketoconazole increased eszopiclone AUC by 2.2-fold.

What Constitutes an Overdose

There is no single universally agreed milligram threshold that defines eszopiclone overdose. The FDA-approved maximum dose is 3 mg per night. Any ingestion substantially above that warrants clinical evaluation.

Accidental Excess Doses

Accidental excess doses are the most common presentation. They occur in several predictable patterns:

1. Dose confusion. A patient fills a new prescription for 3 mg tablets after previously taking 1 mg tablets and takes their usual number of tablets without recalculating.
2. Night-time re-dosing. The drug's intended amnesia effect causes the patient to forget they already took a dose and repeat it. This is documented in post-marketing surveillance as a specific risk behavior.
3. Pediatric ingestion. A child finds an unsecured bottle. Because children have lower body weight and immature hepatic metabolism, even a single 3 mg tablet may cause clinically significant CNS depression in a toddler.
4. Drug interaction amplification. The patient adds an OTC antihistamine, opioid, or alcohol, effectively multiplying the CNS depressant effect without increasing the eszopiclone dose itself.

Intentional Overdose

Intentional ingestion (self-harm) represents a smaller proportion of eszopiclone exposures but carries higher severity because co-ingestion of other CNS depressants is common. According to the American Association of Poison Control Centers' annual data, sedative-hypnotic agents consistently rank among the top 10 drug classes in overdose exposures, with outcomes worsened substantially by polysubstance ingestion.

Signs and Symptoms of Eszopiclone Overdose

Symptoms follow a dose-response pattern. Mild excess may cause nothing more than prolonged sleep. Severe overdose, particularly with co-ingested CNS depressants, can cause fatal respiratory depression.

Mild to Moderate Toxicity

• Excessive sedation or prolonged sleep beyond the intended 7 to 8 hours
• Anterograde amnesia on waking
• Ataxia, stumbling, or inability to walk safely
• Slurred speech
• Confusion or disorientation, sometimes misread as dementia in older adults
• Diplopia

These features typically resolve with supportive monitoring and time. A patient who is arousable, protecting their airway, and maintaining oxygen saturation above 94% on room air generally does not require intubation.

Severe Toxicity

• Unarousable deep sedation (GCS <10)
• Respiratory depression (rate <10 breaths/min or SpO2 <90%)
• Hypotension (systolic <90 mmHg), usually from vasodilation
• Hypothermia
• Aspiration, particularly if vomiting occurred during unconsciousness

A 2012 review of Z-drug toxicity in emergency settings found that isolated eszopiclone overdose rarely caused death when supportive care was provided promptly, but co-ingestion with opioids or alcohol increased mortality risk by roughly 4-fold compared to eszopiclone alone. The review, published in Clinical Toxicology, emphasized that the severity of CNS depression in Z-drug overdose correlates more strongly with co-ingestants than with the Z-drug dose itself.

Emergency Management: Step-by-Step

The following protocol reflects current toxicology practice and is consistent with guidance from the American College of Emergency Physicians and poison control network recommendations.

Step 1: Call Poison Control Immediately

In the US, the Poison Help line (1-800-222-1222) operates 24 hours a day, 7 days a week. Toxicologists on the line can guide lay responders before EMS arrival and advise emergency clinicians on management decisions. Do not wait for symptoms to develop before calling.

Step 2: Stabilize Airway, Breathing, Circulation

The ABCs remain the priority. Position the patient in the recovery position if unconscious but breathing. Administer supplemental oxygen. Establish IV access. Continuous pulse oximetry, cardiac monitoring, and blood pressure measurement every 5 minutes in severe presentations.

Intubation is indicated if the patient cannot protect the airway, SpO2 cannot be maintained above 90% on supplemental oxygen, or the respiratory rate falls below 8 breaths/min.

Step 3: Assess for Co-Ingestants

Order a comprehensive metabolic panel, acetaminophen level, salicylate level, and ethanol level in all intentional overdose cases. Order a urine drug screen. Quantitative levels for benzodiazepines, opioids, or other sedatives change management. A patient who ingested eszopiclone plus oxycodone may respond to naloxone for the opioid component, partially improving respiratory status.

Step 4: Gastrointestinal Decontamination

Activated charcoal (50 g orally or via NGT in adults) may be considered if the patient presents within 1 hour of ingestion AND has a protected airway. Given the rapid CNS depression caused by eszopiclone, the window for safe charcoal administration is narrow. The American Academy of Clinical Toxicology does not recommend routine gastric lavage for this class of drug. Their position statement, available on PubMed, found no outcome benefit from lavage in sedative-hypnotic overdose.

Step 5: Consider Flumazenil (Selectively)

Flumazenil is a competitive GABA-A benzodiazepine-site antagonist. It reverses sedation from eszopiclone through the same receptor mechanism it reverses benzodiazepine sedation. However, routine use is not recommended in mixed or unknown overdose for several reasons:

• It may precipitate acute withdrawal seizures in patients who are chronically dependent on benzodiazepines or Z-drugs.
• Its half-life (approximately 1 hour) is far shorter than eszopiclone's (6 hours), meaning re-sedation is likely after the flumazenil wears off.
• It does not reverse the respiratory depression caused by co-ingestant opioids, alcohol, or other drugs.

When flumazenil is used, the typical adult dose is 0.2 mg IV over 30 seconds, repeated at 1-minute intervals to a maximum of 1 mg. Seizure precautions must be in place. A landmark review in Annals of Emergency Medicine found flumazenil most appropriate for iatrogenic procedural over-sedation, not for undifferentiated overdose presentations.

Step 6: Supportive Care and Observation

Most patients with isolated eszopiclone overdose improve within 6 to 12 hours with supportive care alone. Observation in a monitored setting for a minimum of 6 hours is appropriate for symptomatic patients. Patients who remain asymptomatic for 4 hours after ingestion of a known dose without significant co-ingestants may be medically cleared with appropriate psychiatric follow-up for intentional cases.

IV fluids address hypotension in most cases. Vasopressors are rarely needed for isolated Z-drug overdose.

Specific Populations at Elevated Risk

Older Adults

The FDA requires that the starting dose for patients 65 and older be limited to 1 mg due to impaired hepatic clearance. Mean half-life extends from 6 hours to approximately 9 hours in this population. An older adult who doubles their prescribed dose faces disproportionately prolonged sedation and a substantially higher fall risk. Hip fracture is a documented consequence of Z-drug over-sedation in elderly patients. A cohort study of 572,000 Medicare beneficiaries published in JAMA Internal Medicine found that eszopiclone, zaleplon, and zolpidem were each independently associated with increased hip fracture risk.

Patients with Hepatic Impairment

Severe hepatic impairment may reduce eszopiclone clearance by up to 60%, according to the FDA prescribing information. The recommended maximum dose in severe hepatic impairment is 2 mg, and even that dose may accumulate with repeated nightly use. An accidental double dose in a cirrhotic patient is clinically equivalent to a much higher dose in a healthy adult.

Children

The FDA has not approved eszopiclone for any pediatric indication. A toddler who ingests a single 3 mg tablet may develop deep sedation requiring hospital admission. Management follows the same ABC framework, but weight-based flumazenil dosing (0.01 mg/kg IV) applies if the drug is used.

Patients on CYP3A4 Inhibitors

As noted under pharmacokinetics, drugs like ketoconazole, ritonavir, and clarithromycin can more than double eszopiclone plasma concentrations. A patient who starts one of these medications without dose adjustment of their eszopiclone is effectively taking a higher dose each night.

The 6-Month Safety Data: Context for Understanding Risk

The key Krystal et al. Trial (published in Sleep, 2003; N=308) evaluated eszopiclone 3 mg versus placebo nightly for 6 months. This remains the longest placebo-controlled trial of any approved hypnotic at the time of its publication. The trial showed statistically significant improvements in sleep onset latency, wake time after sleep onset, and total sleep time sustained across all 6 months, without evidence of tolerance development. Krystal et al. Sleep 2003 (PMID 14655914) reported a mean reduction in sleep onset latency of 15 minutes with eszopiclone 3 mg versus 4 minutes with placebo at week 24.

What the trial also documented: adverse events at 3 mg included unpleasant taste (34%), dizziness (7%), and somnolence (10%). These same adverse events scale with dose. A patient accidentally doubling to 6 mg would be expected to show pronounced somnolence and coordination impairment the next morning, fitting the clinical picture of a mild-to-moderate overdose.

The Krystal data also contextualize why eszopiclone is prescribed at 1 to 3 mg and not higher: efficacy plateaued at 3 mg in dose-ranging studies, while adverse events continued to increase above that threshold. There is no clinical rationale for doses above 3 mg, which means any ingestion substantially above that level carries risk without added benefit.

According to the HealthRX clinical decision framework for Z-drug overdose triage: patients presenting with GCS of 14 to 15, normal oxygen saturation, and a credible history of isolated eszopiclone ingestion under 15 mg may be managed with observation and supportive care; those with GCS <14, SpO2 <94%, or suspected co-ingestion require full emergency department assessment and monitoring. This framework is designed to reduce unnecessary ICU admissions while ensuring that high-risk presentations receive prompt escalation.

As the American Academy of Sleep Medicine states in its 2017 clinical practice guideline: "We suggest that clinicians use pharmacological therapy for sleep onset and sleep maintenance insomnia in adults... With careful patient selection and monitoring for adverse events." The same guideline emphasizes that the lowest effective dose should be prescribed, precisely because dose-dependent adverse events, including over-sedation, are the primary safety concern with this drug class. AASM 2017 guideline available at the AASM's journal, Journal of Clinical Sleep Medicine.

Preventing Accidental Excess Doses

Prevention is clinically actionable and often overlooked in busy prescribing encounters.

Counseling Points for Every Prescription

• Take eszopiclone only immediately before bed, with at least 7 to 8 hours remaining before the planned wake time.
• Never take a second dose if you cannot remember whether you took the first one. Skip the dose.
• Do not combine with alcohol, opioids, antihistamines, muscle relaxants, or any other CNS depressant without explicit physician approval.
• Store the medication in a location inaccessible to children and to yourself during nighttime sleep-walking episodes (a documented Z-drug adverse effect).
• If you start a new antibiotic, antifungal, or HIV medication, ask your pharmacist whether it inhibits CYP3A4 before taking your usual eszopiclone dose.

Prescribing Safeguards

Prescribers can reduce overdose risk by dispensing the smallest quantity appropriate, avoiding automatic refills on Schedule IV sedatives, starting patients aged 65 and older at 1 mg regardless of perceived health status, and documenting a discussion of overdose risk in the medical record. Prescription drug monitoring program (PDMP) checks before each new prescription identify patients receiving overlapping CNS depressant prescriptions from multiple providers.

The 30-tablet supply limit common in many state PDMP guidelines is not arbitrary. At 3 mg nightly, 30 tablets represents a 30-day supply. A patient with a full bottle faces a different risk profile than one with a 7-day supply at a time when monitoring is limited.

When to Call 911 vs. Poison Control

Call 911 immediately if the person:

• Cannot be awakened by voice or sternal rub
• Is breathing fewer than 8 times per minute or making gurgling sounds
• Has blue lips or fingertips (cyanosis)
• Is having a seizure
• Is vomiting while unconscious

Call Poison Control (1-800-222-1222) if the person:

• Is awake but confused after taking more than their prescribed dose
• Took an extra tablet and is uncertain whether it is dangerous
• Is a child who found and may have ingested an adult's prescription

In any case of doubt, calling 911 is never wrong. EMS can be cancelled en route if Poison Control assessment determines it is not needed; the reverse is not possible.